Drug Trial Radar · NCT05958407
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
235
Actual
Start
Aug 28, 2023
Primary completion
May 5, 2025
Study completion Sep 22, 2025
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test if treatment with tralokinumab is safe and efficacious in treating moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks for each participant. There will be up to 15 visits for each participant, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants will not receive tralokinumab but are monitored for safety.
Conditions
- Atopic Dermatitis
- Atopic Hand Eczema
Interventions
TralokinumabDrug
After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks
PlaceboDrug
After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear)Time frame: At Week 16
Locations
69 sites in 10 countries. Site status is shown where the registry gives one.
LEO Pharma Investigational Site
Birmingham, Alabama
LEO Pharma Investigational Site
Fort Smith, Arkansas
LEO Pharma Investigational Site
Fountain Valley, California
LEO Pharma Investigational Site
Los Angeles, California
LEO Pharma Investigational Site
Sacramento, California
LEO Pharma Investigational Site
Farmington, Connecticut
LEO Pharma Investigational Site
Hialeah, Florida
LEO Pharma Investigational Site
Plainfield, Indiana
LEO Pharma Investigational Site
Louisville, Kentucky
LEO Pharma Investigational Site
New Orleans, Louisiana
LEO Pharma Investigational Site
Bangor, Maine
LEO Pharma Investigational Site
Caledonia, Michigan
LEO Pharma Investigational Site
Detroit, Michigan
LEO Pharma Investigational Site
Portsmouth, New Hampshire
LEO Pharma Investigational Site
Cortland, New York
LEO Pharma Investigational Site
New York, New York
LEO Pharma Investigational Site
Portland, Oregon
LEO Pharma Investigational Site
Portland, Oregon
LEO Pharma Investigational Site
Nashville, Tennessee
LEO Pharma Investigational Site
Dallas, Texas
LEO Pharma Investigational Site
Frisco, Texas
LEO Pharma Investigational Site
San Antonio, Texas
LEO Pharma Investigational Site
Webster, Texas
LEO Pharma Investigational Site
Brussels, Belgium
LEO Pharma Investigational Site
Edegem, Belgium
LEO Pharma Investigational site
Ghent, Belgium
LEO Pharma Investigational Site
Québec, Canada
LEO Pharma Investigational Site
Québec, Canada
LEO Pharma Investigational Site
Calgary, Alberta, Canada
LEO Pharma Investigational Site
Edmonton, Alberta, Canada
LEO Pharma Investigational Site
Edmonton, Alberta, Canada
LEO Pharma Investigational Site
Red Deer, Alberta, Canada
LEO Pharma Investigational Site
Surrey, British Columbia, Canada
LEO Pharma Investigational Site
Fredericton, New Brunswick, Canada
LEO Pharma Investigational Site
Hamilton, Ontario, Canada
LEO Pharma Investigational Site
Richmond Hill, Ontario, Canada
LEO Pharma Investigational Site
Toronto, Ontario, Canada
LEO Pharma Investigational Site
Windsor, Ontario, Canada
LEO Pharma Investigational Site
Saint-Jérôme, Quebec, Canada
LEO Pharma Investigational Site
Nantes, France
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.